CRSP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 36 cases where CRSP's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 65 cases where CRSP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The 50-day moving average for CRSP moved above the 200-day moving average on September 23, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +2.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRSP advanced for three days, in 209 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRSP as a result. In 78 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for CRSP turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 38 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
CRSP moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CRSP crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 70%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRSP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for CRSP entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.796) is normal, around the industry mean (2.988). P/E Ratio (-10.722) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (454.545) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. CRSP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRSP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
VCEL moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend. In 49 of 60 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on VCEL as a result. In 73 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for VCEL just turned positive on September 16, 2026. Looking at past instances where VCEL's MACD turned positive, the stock continued to rise in 39 of 53 cases over the following month. The odds of a continued upward trend are 74%.
Following a +1.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where VCEL advanced for three days, in 214 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 156 of 225 cases where VCEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 53 of 67 cases where VCEL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VCEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
VCEL broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. VCEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 78 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.665) is normal, around the industry mean (2.988). VCEL has a moderately high P/E Ratio (83.551) as compared to the industry average of (-1.158). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (6.887) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VCEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CRSP | VCEL | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 8 | 33 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | 96 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 78 | |
PRICE GROWTH RATING 1..100 | 62 | 47 | |
P/E GROWTH RATING 1..100 | 50 | 94 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CRSP's Valuation (24) in the Biotechnology industry is significantly better than the same rating for VCEL (96) in the Medical Specialties industry. This means that CRSP’s stock grew significantly faster than VCEL’s over the last 12 months.
CRSP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as VCEL (100) in the Medical Specialties industry. This means that CRSP’s stock grew similarly to VCEL’s over the last 12 months.
VCEL's SMR Rating (78) in the Medical Specialties industry is in the same range as CRSP (96) in the Biotechnology industry. This means that VCEL’s stock grew similarly to CRSP’s over the last 12 months.
VCEL's Price Growth Rating (47) in the Medical Specialties industry is in the same range as CRSP (62) in the Biotechnology industry. This means that VCEL’s stock grew similarly to CRSP’s over the last 12 months.
CRSP's P/E Growth Rating (50) in the Biotechnology industry is somewhat better than the same rating for VCEL (94) in the Medical Specialties industry. This means that CRSP’s stock grew somewhat faster than VCEL’s over the last 12 months.
| CRSP | VCEL | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 79% |
| Momentum ODDS (%) | 2 days ago 81% | 2 days ago 74% |
| MACD ODDS (%) | 2 days ago 83% | 7 days ago 74% |
| TrendWeek ODDS (%) | 2 days ago 80% | 2 days ago 78% |
| TrendMonth ODDS (%) | 2 days ago 80% | 2 days ago 77% |
| Advances ODDS (%) | 8 days ago 82% | 2 days ago 77% |
| Declines ODDS (%) | 10 days ago 81% | 9 days ago 72% |
| BollingerBands ODDS (%) | 2 days ago 86% | 2 days ago 80% |
| Aroon ODDS (%) | 2 days ago 76% | 2 days ago 69% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRSP’s FA Score shows that 1 FA rating(s) are green while VCEL’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRSP’s TA Score shows that 4 TA indicator(s) are bullish while VCEL’s TA Score has 5 bullish TA indicator(s).
CRSP (@Biotechnology) experienced а +0.56% price change this week, while VCEL (@Biotechnology) price change was +1.71% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
CRSP is expected to report earnings on Nov 09, 2026.
VCEL is expected to report earnings on Nov 05, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, VCEL has been loosely correlated with VCYT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if VCEL jumps, then VCYT could also see price increases.
| Ticker / NAME | Correlation To VCEL | 1D Price Change % | ||
|---|---|---|---|---|
| VCEL | 100% | +0.89% | ||
| VCYT - VCEL | 52% Loosely correlated | +3.19% | ||
| AXON - VCEL | 38% Loosely correlated | +2.54% | ||
| MDWD - VCEL | 36% Loosely correlated | N/A | ||
| AMRN - VCEL | 36% Loosely correlated | +0.26% | ||
| CRSP - VCEL | 34% Loosely correlated | +1.24% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TOV | 32.61 | 0.21 | +0.66% |
| JLens 500 Jewish Advocacy U.S. ETF | |||
| IAUG | 30.28 | 0.09 | +0.30% |
| Innovator International Developed Power Buffer ETF August (IAUG) | |||
| JBK | 25.75 | N/A | N/A |
| Lehman ABS Corp | |||
| EWS | 31.32 | -0.01 | -0.03% |
| iShares MSCI Singapore ETF (EWS) | |||
| RDYY | 14.94 | -0.21 | -1.39% |
| YieldMax RDDT Option Income Strategy ETF (RDYY) | |||